In IDO-expressing melanoma and colon cancer, inhibition of CSF-1R signaling can functionally block tumor-infiltrating MDSCs and enhance antitumor T-cell responses, thus sensitizing IDO-expressing tumors to immunotherapy with T-cell checkpoint blockade (85). The gene discussed is CSF1R; the disease is neoplasm.